Medtronic PLC (NYSE:MDT) stock fell 3.49% (As on May 22, 11:23:33 AM UTC-4, Source: Google Finance) after the company surpasses market’s expectations for the fourth quarter of FY25. In the fiscal fourth quarter, Cardiovascular revenues increased 7.8% organically to $3.37 billion. Within this, Cardiac Rhythm & Heart Failure sales totaled $1.75 billion, up 10.3% year over year organically. Revenues from Structural Heart & Aortic rose 8.3% organically to $955 million. Coronary & Peripheral Vascular revenues grew 1% organically to $667 million. In the Medical Surgical portfolio, worldwide sales totaled $2.24 billion, up 2% year over year organically. While Surgical & Endoscopy revenues edged up 1.7% organically to $1.73 billion, Acute Care & Monitoring revenues increased 3.1% organically to $508 million. In Neuroscience, worldwide revenues of $2.64 billion were up 3.7% year over year organically. Cranial & Spinal Technologies sales reached $1.35 billion, up 4.4% year over year organically. Specialty Therapies revenues totaled $766 million, down 1.6% year over year organically. Neuromodulation revenues grew 10.2% organically to $524 million. Revenues in the Diabetes group rose 12% organically to $739 million.

Further, MDT has announced its intent to separate its Diabetes business into a new standalone company (New Diabetes Company). This strategic decision for both Medtronic and New Diabetes Company will create a more focused Medtronic, with a more simplified portfolio in high margin growth markets. At the same time, it will create an independent, scaled leader in diabetes, focused on accelerating innovation and differentiated as the only company to commercialise a complete ecosystem to address intensive insulin management. The separation is expected to be completed within 18 months through a series of capital markets transactions, with a preferred path of an initial public offering (IPO) and subsequent split-off. The separation is expected to unlock value for Medtronic and its shareholders, as it creates a New Diabetes Company shareholder base more aligned with its financial profile and is expected to be accretive to Medtronic gross margin, operating margin, and earnings per share (EPS).

MDT in the fourth quarter of FY25 has reported the adjusted earnings per share of $1.62, beating the analysts’ estimates for the adjusted earnings per share by 2.5%, according to the Zacks Consensus Estimate. The company had reported the adjusted revenue growth of 3.9 percent to $8.93 billion in the fourth quarter of FY25, beating the analysts’ estimates for revenue by 1.1%.

Full-year 2026 adjusted EPS is expected to be in the range of $5.50-$5.60 and projects organic revenue growth of 5%.